SLC5A2 and Insulin resistance: Physiologically, SGLT2 inhibitors seem to have hepatoprotective impact, including the reduction of oxidative stress, glucagon-driven hepatic lipogenesis, systemic inflammation, and insulin resistance in addition to enhancing glycemic control.